Patent Application
20140308298
The present invention relates to markers for diagnosing an androgen-independent prostate cancer tumor growth, and the use of antibodies anti-adrenomedullin and/or anti-adrenomedullin receptor for treating an androgen independent prostate cancer.
Prostate cancer (CaP) is the most-diagnosed malignant growth in men and is the second-leading cause of male cancer deaths in the majority of Western countries. The cancerous gland usually contains multiple independent and genetically distinct lesions, demonstrating heterogeneity of the disease (1, 2). Because pathologic growth of the prostate is controlled largely by steroid androgens, treatment of locally advanced or metastatic disease relies heavily on hormonal therapies that target the androgen receptor (AR). A major limitation of hormonal therapy, however, is that it offers only temporary relief; the cancer eventually reappers as an androgen-independent (AI) lesion characterized by aggressive growth and invasion of distal organs (3). Whether it is clonal expansion or adaptation, development of AI prostate cancer clearly shows that those factors other than, or together with, androgen must exist to provide survival and growth instructions to the AI cells.
Therefore, there is a need for accurate diagnosis markers of AI prostate cancer.
Rocchi et al. have reported the expression and characterization of adrenomedullin (AM) in the prostate-cancer patients with high Gleason's score suggesting a role of AM in prostate cancer growth and hormonal escape (4). At the time of its discovery AM was noted to be a potent vasodilator (5), and it has subsequently been linked to the regulation of numerous vascular responses, including blood pressure, salt and water intake, and angiogenesis (6-8), as well as regulator of cell growth (7, 9-11). These functions were discovered due to many physiological studies and are highlighted in knockout studies in which AM null mice die in utero from extreme hydrops fetalis, vascular and lymphatic abnormalities (12, 13). AM is expressed in a variety of malignant tissues and was shown to be mitogenic for human cancer cell lines including lung, breast, colon, glioblastoma, pancreas, kidney and prostate lineages in vitro (4, 8, 14-19). Evidence for the importance of AM-induced angiogenesis in tumor growth is that inhibition of AM action by neutralizing antibodies or AM antagonist (hAM22-52) blocks the growth of tumor xenografts in vivo (15, 16). The density of blood vessels in anti-AM antibody-treated tumors is decreased; supporting the notion that AM plays roles in angiogenesis, vasculogenesis and/or vessel stabilization (7, 8, 11, 15, 20, 21). The coupling of these functions with the potent effects of AM on cell migration, growth, and apoptosis have led to the hypothesis that AM may be a key player in tumor growth and metastasis (22, 23).
AM transduces its effects through the G protein-coupled receptor calcitonin receptor-like receptor (CLR), with specifity for AM being conferred by the receptor activity modifying protein −2 (RAMP2) and −3 (RAMP3) (24). The ability of CLR/RAMP2 and CLR/RAMP3 to respond with high affinity to AM implies the existence of two molecularly distinct AM receptors referred as AM1 and AM2 receptors, respectively (25). Mice deficient in the components of AM receptors, CLR and RAMP2 develop edema and embryonic lethality at midgestation (26). Another study of RAMP2 gene-targeted mice concludes that the embryonic edema observed in these mice is due to hyperpermeable blood vessels (27). Multiple second messenger responses to AM mediate a multitude of biological functions (6, 10). The activation of the receptor by AM has commonly been linked to elevation of cAMP (10). There are reports demonstrating that AM can signal through other mechanisms such as elevation of free intracellular Ca2+ levels (28), activation of cGMP-NO pathway (10), activation of cGMP-PKG pathway (29), Ras-Raf pathway (21), K+-ATP channels (30), or PI3-kinase/Akt, FAKinase and MAPkinase pathways (20).
It has previously been reported the presence of AM in human prostate tissues, prostate carcinoma, and prostate cancer cell lines (4, 31, 32). Some of the inventors have shown an increase in AM levels in LuCaP 23.1 xenografted tumors after castration (33). Abasalo et al. have shown that AM prevents apoptosis in prostate cancer cells (34). Recently, Joshi et al. demonstrated that AM up-regulates interleukin-13 receptor α2 chain in prostate cancer in vitro and in vivo revealing a novel role of AM in sensitizing certain types of prostate tumors to IL-13R-directed therapeutic agent (35). Some of the inventors have reported that the expression of AM is down-regulated by androgen in androgen-sensitive LNCaP cells in vitro and in vivo. Further, in the absence of androgen, AM promotes prostate cancer tumor growth (29).
The inventors have studied the cellular and molecular mechanisms activated by AM to promote CaP growth in androgen-independent manner. The inventors have used the hormone independent prostate cancer cell line Du145 as model to investigate the expression of AM system (AM, AM1 and AM2 receptors) and to evaluate its role in vitro as well as in vivo. The effect of anti-AM polyclonal antibody (αAM) on tumor growth was further studied in a mouse heterotopic and orthotopic prostate-cancer xenograft models.
International Application WO 02/098358 discloses general methods for diagnosing (by detecting specific polynucleotides or by immunoassay) and for treating malignant or non-malignant androgen-dependent prostate cells, prostate cells undergoing androgen withdrawal, and androgen-independent prostate cancer.
The inventors have shown that αAM decreases the proliferation and invasion of Du145 cells in vitro and inhibits the growth of androgen-independent Du145 tumor xenografts by targeting tumor angiogenesis and lymphangiogenesis. The inventors have also shown that AM is one of the major factor(s) involved in the lymphatic vessels generation and/or lymphatic vessel stabilization.
These results support that interference with the function of AM following androgen ablation represent a tractable system for the treatment of CaP growth at the hormone-independent escape and inhibition of tumor metastasis.
These results further support that determining the amount of at least one adrenomedullin receptor and optionally the amount of adrenomedullin in a prostate cancer cell can be useful for diagnosing a regression or a progression of an androgen-independent prostate cancer tumor growth. A subject, for which an androgen-independent prostate cancer tumor growth progression has been diagnosed can be treated with an anti-adrenomedullin antagonist antibody and/or at least one anti-adrenomedullin receptor antagonist antibody.
Accordingly, in a first aspect, the present invention provides a method of monitoring the tumor growth of an androgen-independent prostate cancer in a subject, comprising the step of:
a) determining the amount of at least one adrenomedullin receptor selected among the proteins CLR, RAMP2 and RAMP3, in a prostate cancer cell obtained from said subject, and
b) comparing the amount determined in step a) with amounts previously obtained from said subject or with the standard amount of said adrenomedullin receptors,
a decrease in amount of at least one adrenomedullin receptor constituting a marker of the regression of said androgen-independent prostate cancer tumor growth and an increase in amount of at least one adrenomedullin receptor constituting a marker of the progression of said androgen-independent prostate cancer tumor growth.
In a preferred embodiment of said method, in step a) the amount of adrenomedullin in a prostate cancer cell obtained from said subject is further determined and in step b) the amount of adrenomedullin determined in step a) is compared with amounts previously obtained from said subject or with the standard amount of adrenomedullin, a decrease in amount of at least one adrenomedullin receptor and adrenomedullin constituting a marker of the regression of said androgen-independent prostate cancer tumor growth and an increase in amount of at least one adrenomedullin receptor and adrenomedullin constituting a marker of the progression of said androgen-independent prostate cancer tumor growth.
The prostate cancer cells are generally obtained from a prostate tissue sample carried out by biopsy.
As used herein, the term “subject” refers to mammal, preferably a human.
As used herein, the term “adrenomedullin receptor” refers to the proteins CLR, RAMP2 and RAMP3 respectively. These proteins can be in a form of a protein complex CLR/RAMP2, CLR/RAMP3, RAMP2/RAMP3 and CLR/RAMP2/RAMP3. These proteins CLR, RAMP2, RAMP3 are well known to a person skilled in the art (24). By way of example, an amino acid sequence of the proteins CLR, RAMP2, RAMP3 are available under the accession numbers gi|5031621, gi|118572585 and gi|5032023 in the GENBANK database respectively.
Advantageously, the amount of at least one, preferably at least two, more preferably the three adrenomedullin receptor(s) and optionally the amount of adrenomedullin are determined.
As used herein, the term “standard amount of refers to the reference amount of at least one adrenomedullin receptor and/or the reference amount of adrenomedullin in prostate cells which have been determined in a large population of subjects not suffering from an androgen-independent prostate cancer.
The method according to the invention can be performed in vitro, ex vivo or in vivo.
In a preferred embodiment of step a) of the method according to the present invention, said tumor cell is contacted with an antibody or antibodies binding at least one adrenomedullin receptor and optionally adrenomedullin.
The antigen-antibody complexes formed in step a) can then be revealed, by any suitable means, for example by EIA, ELISA, RIA, immunofluorescence or immunohistochemistry, preferably immunohistochemistry.
As used herein, the term “antibody” encompasses polyclonal or monoclonal antibodies, natural, synthetic or recombinant antibodies, camelid single-domain antibodies, chimeric antibodies such as a humanized antibodies, and the fragments thereof (e.g. Fab′2, Fab, Fv, scFv) having retained their ability to bind adrenomedullin, CLR, RAMP2 and/or RAMP3.
The term “recombinant antibody” is intended to mean an antibody produced by genetic engineering, for example by cloning and gene amplification
The term “synthetic antibody” is intended to mean an antibody produced by enzymatic and/or chemical synthesis.
The term “chimeric antibody” is intended to mean an antibody from a particular animal species or a particular class of antibodies, which includes all or part of a heavy chain and/or light chain of an antibody from another species or another antibody class. The term “chimeric antibody” may also designate a multispecific antibody, i.e., specific to at least two different epitopes. The multispecific antibodies can be obtained from said antibody fragments as defined above. Advantageously, said multispecific antibody binds to two or three different epitopes selected from an epitope from adrenomedullin, an epitope from CLR, an epitope from RAMP2 and an epitope from RAMP3. Therefore, an anti-adrenomedullin antagonist antibody and an anti-adrenomedullin receptor antagonist antibody can be in a form of single multispecific antibody. By way of example a bi-specific antibody includes an antibody which binds to a complex selected from AM/CLR, AM/RAMP2, AM/RAMP3, CLR/RAMP2, CLR/RAMP3 and RAMP2/RAMP3, preferably a complex selected among CLR/RAMP2, CLR/RAMP3 and RAMP2/RAMP3. By way of example, a tri-specific antibody includes an antibody which binds to a complex selected among AM/CLR/RAMP2, AM/CLR/RAMP3, AM/RAMP2/RAMP3 and CLR/RAMP2/RAMP3, preferably CLR/RAMP2/RAMP3 complex. Advantageously again, said multispecific antibody binds to adrenomedullin and the proteins CLR, RAMP2 and RAMP3.
The term “humanized antibody” refers to a human immunoglobulin in which the residues of the CDRs (Complementary-Determining Region) that form the binding site to the antigen are replaced by those of a non-human monoclonal antibody with a desired specificity, affinity and/or activity.
The antibodies and antibody fragments can be prepared by conventional techniques well known to a person skilled in the art. By way of example, anti-AM, -CLR, -RAMP2 or -RAMP3 antibodies can be obtained as described by Fernandez-Sauze et al. (7), Ouafik et al. (15) and in International Applications WO 2007/045927 and WO 2010/012911.
Advantageously, said antibodies can be obtained by immunizing a suitable animal with a chimeric polypeptide (antigen) comprising or consisting of four peptides of at least 6 contiguous amino acid, derived from adrenomedullin and an extracellular domain of the proteins CLR, RAMP2 and RAMP3 respectively, said chimeric polypeptide being capable of inducing, in said animal immunized with said chimeric polypeptide, the production of polyclonal antibodies that bind to adrenomedullin, CLR, RAMP2 and RAMP3. The immunized animal can be a mammal, such as a horse, goat, rabbit, rat, mouse, llama and camel.
A chimeric polypeptide (antigen) as defined above, which mimics the structure of the extracellular domains of proteins CLR, RAMP2 and RAMP3, can induce the production in an immunized animal, of a conformational antagonist antibody that specifically recognize these proteins CLR, RAMP2 and RAMP3 in their native form or protein complexes, that is to say, the complex AM/CLR, AM/RAMP2, AM/RAMP3, CLR/RAMP2, CLR/RAMP3, RAMP2/RAMP3, AM/CLR/RAMP2, AM/CLR/RAMP3, AM/RAMP2/RAMP3, CLR/RAMP2/RAMP3 or AM/CLR/RAMP2/RAMP3.
Advantageously, each of the following peptides can be used to immunize an animal or to produce a chimeric polypeptide useful for immunizing an animal, for obtaining antibodies as defined above:
The order of the different peptides derived from adrenomedullin and adrenomedullin receptors CLR, RAMP2 and RAMP3 respectively may be randomly chosen for producing the chimeric polypeptide. However, it is preferable to produce a chimeric polypeptide comprising or consisting, from the N-terminus to the C-terminus, a peptide derived from adrenomedullin, a peptide derived from CLR, a peptide derived from RAMP3 and a peptide derived from RAMP2. Preferably, the chimeric polypeptide (antigen) has the amino acid sequence SEQ ID NO: 9 (referred to as ch2):
Said antibody can be linked, directly or indirectly, covalently or non-covalently to a diagnostic agent selected from the group consisting of:
Said diagnostic agent can be directly and covalently linked to said antibody either to one of the terminal ends (N or C terminus) of the antibody, or to the side chain of one of the amino acids of the antibody. The substance of interest can also be indirectly and covalently linked to said antibody by a connecting arm (i.e., a cross-linking reagent) either to one of the terminal ends of the antibody or to a side chain of one of the amino acids of the antibody. Linking methods of a substance of interest to an antibody are known in the art.
Many chemical cross-linking methods are also known in the art. Cross-linking reagents may be homobifunctional (i.e., having two functional groups that undergo the same reaction) or heterobifunctional (i.e., having two different functional groups). Numerous cross-linking reagents are commercially available. Detailed instructions for their use are readily available from the commercial suppliers.
Methods for detecting and quantifying adrenomedullin receptors and optionally adrenomedullin by using anti-adrenomedullin receptor antibodies and optionally anti-adrenomedullin antibodies are known to a person skilled in the art (7, 15).
In another preferred embodiment of step a) the method according to the present invention, when it is carried in vitro or ex vivo, the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a prostate cancer cell is determined by detecting and quantifying RNA sequences coding an adrenomedullin receptor and optionally adrenomedullin, by using a quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR) assay.
Methods for detecting and quantifying RNA sequences coding an adrenomedullin receptor and optionally adrenomedullin by using a Q-RT-PCR assay are known to a person skilled in the art (4, 15, 29).
In a second aspect, the present invention provides a pharmaceutical composition comprising an anti-adrenomedullin (anti-AM) antagonist antibody and/or at least one anti-adrenomedullin receptor (anti-AMR) antagonist antibody for use as a medicament for treating an androgen-independent prostate cancer.
The anti-AM and anti-AMR antibodies of said composition are antagonist antibodies possessing the following properties:
These properties can be verified by conventional tests which make it possible to evaluate the binding activity of an antibody to a protein or to a peptide or the inhibition of this activity, in particular by direct and competition ELISA tests.
Advantageously, said pharmaceutical composition also comprises a pharmaceutically acceptable carrier.
As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes, cationic lipids and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with a therapeutic agent as defined hereabove, use thereof in the composition of the present invention is contemplated.
In addition to the preceding features, the invention further comprises other features which will emerge from the following description, which refers to examples illustrating the present invention, as well as to the appended figures.
Cultured cells: The human-derived CaP cell lines LNCaP androgen-dependent, PC3 and Du145 androgen-independent were obtained from American Type Culture Collection (Rockeville, Md.) and cultured in RPMI 1640 (Invitrogen Life Technologies Inc., Paris, france) as previously described (4). The lymphatic endothelial cells (LECs) were obtained from Lonza (Basel, Switzerland) and cultured in EGM-2MV complemented with 5% FBS and growth factors.
Human prostate specimens: Human prostate samples from CaP (n=8) of high Gleason's scores were obtained from the Department of Urology (AP-HM, Marseille, France). All of the tissue procurement protocols were approved by the relevant institutional committees (Aix-Marseille Université) and were undertaken under informed consent of each patient or their relatives.
RNA preparation and analysis: Total RNA was prepared from Du145, PC3, LNCaP cells and LECs, reverse transcribed to cDNA and quantified as described (29).
Development and characterization of anti-human AM polyclonal antibody: The anti-human AM polyclonal antibody (αAM) was developed and characterized as previously described by Ouafik et al., 2002 (15). Particularly, the polyclonal antibody against human AM was developed by use of the synthetic peptide corresponding to the entire AM1-52 amide peptide (Bachem, Switzerland). Female New Zealand rabbits received injections at multiple subcutaneous sites with 300 μg of synthetic peptide emulsified with complete Freund's adjuvant. Then the rabbits were further immunized at 2.5-week intervals with 120 μg of AM1-52 amide emulsified with incomplete Freund's adjuvant (42). The anti-sera obtained after the fourth booster injection were screend for anti-AM activity, and then affinity purified on rProtein A Sepharose Fast Flow columns (GE Healthcare, Europe). The anti-AM polyclonal antibody (purified IgG) showed very low cross-reactivity (<7%) with AM-related peptides such as AM22-52 amide, AM26-52 amide, and AM13-37 amide. Clacitonin, CGRP1-37 amide, CGRP8-37 amide, and amylin showed insignificant anti-AM antibody binding (<0.1%) despite some homology with AM. It was also demonstrated that anti-AM antibody blocked the binding of 125I-AM to its cell-surface receptor on DU145 cells in a dose-related manner.
Western blotting analysis: Cell extracts were prepared and processed for CLR, RAMP2 and RAMP3 western blot analysis as described (29). Immunoblotting of phospho-c-Raf, phospho-MEK1/2, phospho-ERK1/2, and ERK1/2 was performed using MAPK-phospho-ERK1/2 pathway samples kit (Cell Signaling Technologie, Inc.).
Cyclic AMP assay: Du145 cells treated with AM (10−7-10−9 M) in the presence of IBMX (10−4 M) were prepared to measure the intracellular amount of cAMP using the cAMP enzyme immunoassay Biotrak (EIA) System (GE Healthcare) according to the supplier's protocol.
Cell migration and invasion assays: The migration and chemoinvasion were assessed using a modified Boyden chamber assay (7). Du145 (15×10−3), LNCaP (50×10−3), and PC3 (30×10−3) cells were added to the upper compartment during 6 h. For LECs, (30×10−3) cells were added during 48 h for invasion and 20 h for migration.
Cell proliferation assay: The effects of AM, αAM and control IgG on cell proliferation was examined at the indicated time points as described (19).
Experimental protocol for animals: Athymic NMRI (nu/nu) nude mice (Harlan, Gannat, France) were purchased at four weeks of age. Respectively 5×106 and 1×106 of Du145 cells were implanted subcutaneously in the right flank or orthotopically in the dorsal prostate in nude mice male (n=30). When the tumors were 700±100 mm3 in size, animals were randomly divided into two groups. One group (n=20) received intraperitoneal (i.p.) injection of αAM (330 μg of purified IgG) and control group (n=10) received an irrelevant antibody (IgG of the same isotype). αAM half-life in nude mice was determined to be 3 to 4 days.
Tumor xenografts were analyzed as described (36). Particularly, athymic NMRI (nu/nu) nude mice (Harlan, Gannat, France) were purchased at four weeks of age. Suspension of Du145 cells (5×106 in 200 ∥l PBS) were subcutaneous (s.c.) injected into the right flank of male mice (n=30). Tumors sizes were determined with a dial-caliper measurements, and the tumor volume was calculated as width×length×height×0.5236 (for ellipsoid form). Mice with s.c. tumors greater than 1.5 cm in diameter were killed in accordance with University of Aix-Marseille animal rights Committee guidelines. αAM half-life in nude mice was determined to be 3 to 4 days. When the tumors were 700±100 mm3 in size, animals were randomly divided into two groups. One group (n=20) received intraperitoneal (i.p.) injection of αAM (330 μg of purified IgG) as a suspension in PBS in a volume of 0.2 ml every 3 days. A control group (n=10) received an irrelevant antibody (IgG of the same isotype). Tumors sizes were measured every 2 days, and mice were sacrificed at 12 weeks after injection. Tumors were stored in liquid nitrogen or embedded in Paraffin for pathologic studies and immunohistochemistry.
For orthotopic injections, the mice were anesthetized with i.p. injections of xylazine (10 mg/kg) and ketamine (50 mg/kg). An incision was made through the abdominal muscles to expose the bladder and seminal vesicles, which then were delivered through the incision to expose the dorsal prostate. Du145 cells (1×106) were injected into dorsal lobe in a 50 μl volume. Treatment was initiated one month after tumor cell implantation with three weekly i.p. injections of 330 μg of αAM (n=10) or control IgG (n=10). Treatment was continued until the experiments were terminated. After the mice were killed, tumors were immersed in 4% paraformaldehyde, washed in phosphate-buffered saline (PBS), and processed for whole mount-staining.
For the experiments that concern LNCaP cells, mice (n=20) bearing heterotopic LNCaP tumors (˜500 mm3) were divided into two groups. A group of animals (n=10) was castrated and separated into two groups which received an i.p. injection of 330 μg of αAM (n=5) or control IgG (n=5) every three days. The same paradigm was applied to non castrated animals.
Immunohistochemistry and image analysis: Sections of paraffin-embedded samples of human CaP specimens and subcutaneous and orthotopic tumors were analyzed as described (4, 36). To assess the lymphatic vessels, a goat polyclonal anti-LYVE-1 antibody (1/100; R&D systems) was used. Particularly, sections of paraffin-embedded samples (4 μm) of human CaP specimens were tested for the presence of AM, CLR, RAMP2, RAMP3 and NSE after heat-induced antigen retrieval in citrate buffer (pH 6) at 97° C. for 40 min. Optimal dilution for anti-AM (4) and anti-CLR (36) antibodies was 1/2000, anti-RAMP2 (36) antibody was 1/750, anti-RAMP3 (36) antibody was 1/1500 and anti-NSE antibody (Dako, Glostrup, Denmark) was 1/200. Incubation was maintained overnight at 4° C. and followed by a second layer containing biotynylated anti-rabbit antiserum (Histostatin plus, Zymed). The next treatment was with avidin-biotin peroxidase complex kit (Histostatin plus, Zymed). Note that endogen biotin and endogen peroxidases were respectively neutralized by a biotin-blocking system (Dako, Glostrup, Denmark) and 3% H2O2.
Paraffin blocks of subcutaneous and orthotopic tumors were cut to 6 μm sections and stained with hematoxylin and eosine (H&E) for morphology evaluation. Immunohistochemistry was carried out using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, Calif., USA). Thin (6 μm) sections were incubated with anti-von Willebrand factor antibody (anti-vWF) (1:400; Dako, Glostrup, Denmark), or anti-a-Smooth muscle actin antibody (anti-aSMA) (1/80; Dako, Glostrup, Denmark) were applied to assess tumor vascularity, or a goat polyclonal anti-LYVE-1 antibody (1/100; R&D systems) to assess the lymphatic vessels. The primary antibodies were detected with the appropriate Alexa Fluor 488 or 568 secondary antibody conjugates (Molecular Probes/Invitrogen Life Technologies). All fluorescently labeled samples were mounted with Vectashield mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen Life Technologies) and analyzed with a compound fluorescent microscope. For nonimmunofluorescence staining, detection was carried out using a DAB chromogen. Negative control slides were obtained by omitting the primary antibody.
Statistical analysis: Data are expressed as mean±SEM from at least three independent experiments. One-way analysis of variance (ANOVA) or Fisher's PLSD test (Statview 512; Brain Power Inc., Calabasas, Calif., USA) was used for statistical analysis. A p value<0.05 was considered significant and is indicated with an asterisk in the figures. A double and triple asterisk indicates p<0.01 and p<0.001, respectively.
Immunocytochemistry of AM, CLR, RAMP2, RAMP3 and NSE proteins:
The expression and localization of the NSE, AM, CLR, RAMP2 and RAMP3 proteins were evaluated by immunohistochemistry (
Exogenous AM Stimulates Androgen-Independent Cancer Cell Line Growth, cAMP Activity and Invasion:
The androgen independent Du145 cell line expressed AM1 and AM2 receptors (
Next, it was analyzed the effect of exogenous addition of AM on Du145 cell invasion. The addition of AM (10−7 M) to the bottom wells increased the number of invading cells. The data demonstrated that AM induced significant effects on invasion reaching 92±22% (p<0.001) compared with control (
ERK and Akt is known to regulate cell proliferation and this signaling pathway was reported to function downstream of the AM/cAMP pathway (37, 38). Therefore, it was investigated the activity (phosphorylation) of ERK and Akt pathways in cultured Du145 cells after stimulation with AM. It was first measured the phosphorylation of cRaf and it was found that AM (5×10−7 M) increased cRaf phosphorylation as early as 2 min and declines to reach the control levels up to 10 min (
αAM Inhibits Growth of Androgen-Independent Prostate Cancer Tumor Xenografts:
It was further wished to analyze the effect of endogenous AM on tumors developed in vivo in immunodeficient mice. We sought to determine whether AM is just a classic growth factor involved in tumor cell proliferation in vivo, or it has more complex role to sustain tumor growth by performing a stable angiogenesis and lymphangiogenesis to produce a functional blood and lymphatic vessels. In the first series of experiments, tumor cells were injected subcutaneous (s.c.) in the flanks of male athymic mice (nu/nu), and once tumors reached a size of 700±100 mm3, mouse started to receive i.p. injection of 330 μg of αAM or control rabbit IgG of irrelevant specificity every 3 days for 4.85 consecutive weeks. Tumor growth was suppressed in αAM-treated tumors (p<0.001) (
The effect of αAM on tumor growth was tested by using the Du145 orthotopic model. As compared with the s.c. model for tumor growth, the orthotopic model requires implantation of tumor cells directly in the mouse prostate. Mice received i.p. injection of 330 μg of αAM or control IgG three times a week until sacrifice for analysis (
In the Absence of Androgen, αAM Inhibits LNCaP Tumor Growth In Vivo:
Following castration, LNCaP xenografts grew with androgen-independent manner and present a growth pattern comparable to one observed for hormone-independent cells such as Du145 cells. To further investigate whether the endogenous AM expressed upon castration might be involved somehow in tumor growth in castrated animals, i.p. administration of αAM or control IgG was given to castrated and non-castrated animals bearing heterotopic LNCaP tumor xenografts a three times a week. The growth of xenografts was significantly decreased by αAM treatment in castrated animals as compared to control IgG group (
AM Blockade Depletes Endothelial Cells and Pericytes in Tumors:
Histological examination of Du145 heterotopic (
αAM blocks the development of tumor-associated lymphangiogenesis: Lymphatic vessel growth is associated with a number of pathological conditions, including tumor metastasis and inflammation (39-41). To determine whether αAM treatment inhibits tumor-associated lymphangiogenesis, primary tumors from Du145 orthotopic tumor-bearing animals treated with αAM or control IgG were evaluated for tumor-associated lymphatic vessels by immunostaining for LYVE-1 (lymphatic vessel endothelial receptor 1) (
Also, the smooth muscle cells, surrounding the collecting vessels in tumor tissue were eradicated in αAM-treated tumors compared to control-IgG treated tumors. Furthermore, disintegration between lymphatic endothelial cells occurred in the lymphatic vessels of αAM-treated tumors but not in the lymphatic vessels of control-IgG-treated tumors. Quantitative evaluation of the number of lymphatic vessels revealed a significant reduction specifically in αAM-treated tumor tissues, compared with in control IgG-treated tumors (p<0.001;
To address the question of the reduction of lymphatic vessels number upon αAM treatment, it was hypothesized that AM is necessary somehow for lymphatic endothelial cells (LECs) survival suggesting that αAM treatment may induce LECs death by apoptosis. The apoptotic cells, as revealed by immunostaining with Mab 7-26 antibody (ssDNA), were predominantly located within the vascular lining and costaining with an antibody for LYVE-1 identified them as LECs. The apoptotic index of the αAM-treated tumors increased with treatment and reached a significant increase of ˜6-fold when compared with control tumors (p<0.001;
Progression of CaP towards androgen-independent status is an oncological challenge. The mechanisms responsible for the transformation of this cancer are not well understood. It was previously observed that AM was expressed in CaP (4). In the current study, it was further investigated the potential role of AM as an autocrine/paracrine factor in the disease. It was demonstrated the presence of AM and AM receptors (AM1 and AM2 receptors) suggesting the possibility of AM being an autocrine/paracrine growth factor in androgen-independent cancer of prostate.
To examine the possibility of an autocrine effect of AM on androgen-independent CaP Du145 cells, it was determined the effect of exogenous addition and inhibition of AM in vitro. The above data showed that AM significantly increased Du145 cell proliferation, invasiveness, stimulation of cAMP, and the activation of the Erk-mitogen-activated protein kinase (MAPK) pathway. These data indicate that hormone independent CaP cells are able to respond to AM in ways that would expected to further the aggressiveness of androgen-independent CaP. Importantly, it was further found that αAM inhibited the basal levels of CaP androgen-independent cell proliferation and invasion in vitro. These data indicate that inhibition of the interaction of AM produced by Du145 cells with cellular receptors reduces these cellular functions. Taken together, these data strongly support the conclusion that AM can act in an autocrine manner in androgen-independent CaP. The presence of autocrine loop that involves AM and its own receptors suggests that foci of AM-producing cells in a tumor could stimulate cells expressing AM receptors via autocrine/paracrine mechanisms.
The presence of AM receptors in CaPs confirms that AM must play a role in situ. The important role of AM in tumor progression by promoting tumor proliferation, inhibiting apoptosis (22) and promoting angiogenesis (7, 8, 15, 16) has been well established. All these activities may be relevant in prostate cancer. To examine tumor growth in response to αAM therapy, it was developed heterotopic xenograft of Du145 cells. The above results demonstrated that the αAM could be efficiently delivered in vivo and significantly suppress the growth of established Du145 xenografts. After 15 days of treatment, tumors in mice treated with control IgG grew progressively to a size that led to sacrifice, whereas the volume of the αAM-treated tumors was stabilized and reached at least 80% decrease when compared with the controls. AM has been shown to be involved in the multistep process of angiogenesis (7, 22). After αAM treatment for twenty days, the immunostaining of tumor sections with anti-vWF antibody demonstrated that more than 84% of the vessels disappeared with a clear decrease of the number of endothelial cells. the data demonstrate that the density of vessels with lumen was decreased in the antibody-treated tumors suggesting strongly that AM system must be involved in neovascularization and/or vessel stabilization as it was previously demonstrated for xenografts of glioblastoma (U87), lung (A549) and colorectal cancer (HT-29) (15, 36). Since Du145 cell growth in vitro is inhibited by αAM, the inhibition growth of the corresponding tumor xenografts in vivo could be a result of a combined effect on tumor cell growth associated with the effect on tumoral neoangiogenesis. The inhibition of tumor growth by αAM treatment of LNCaP xenografts in castrated animals reinforce the data obtained with Du145 xenografts and brought strong evidence demonstrating that endogenously expressed AM might be one of key players in tumor growth following androgen ablation. These data highlight the key role that may have AM in the absence of androgen by its effect on tumor cell growth as well as on tumor microenvironment by inducing and stabilizing a neovascularization leading the nutrient and oxygen supply. Interestingly, the normal vascularization in normal tissues was not affected by αAM treatment suggesting that AM system (ligand and its receptors) is well expressed and activated as well in pathological situation such as tumor growth or physiological events such as wound healing or menstrual cycle.
It is well known that subcutaneous tumors have a different vascularity than orthotopic tumors, in the purpose to evaluate the effect of αAM in orthotopic model, it was developed orthotopic xenograft of human prostate cancer of androgen-independent Du145 cells. Treatment with αAM caused a clear inhibition of tumor growth characterized at the histological level by a vascular disruption with decreased microvessel density as observed in heterotopic xenografts. However, it was observed that subcutaneous. tumors are more vascularized than orthotopic tumors even in control tumors. To determine whether lymphatic vessels might be dominant in CaP orthotopic xenografts rather than blood vessels, it was analyzed the lymphatic vessels using a murine LYVE-1 antibody. LYVE-1+ lymphatic vessels were observed within the tumor in control-treated specimens and were completely devoid within the αAM-treated tumors. Importantly, αAM treatment was not observed to impair pre-existing lymphatic vessels as the density of LYVE-1-positive lymphatic endothelium detected in the normal tissue was identical in control versus treated animals. Prolonged inhibition does not affect adult lymphatic vessels, indicating that AM/AM1 and AM/AM2 signalling is not required for the maintenance of the lymphatic vasculature in adulthood. This suggests that αAM specifically targets tumor lymphatic vessels but not normal lymphatic vessels underlying the important role of AM towards LECs in terms of proliferation, migration, invasion and organization and/or stabilization of functional lymphatic vessels during tumor growth.
| Number | Date | Country | Kind |
|---|---|---|---|
| 11306438.0 | Nov 2011 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IB2012/056116 | 11/2/2012 | WO | 00 | 5/1/2014 |
